Company news
Kyowa Kirin Co., Ltd. (TSE:4151) news
Every Kyowa Kirin Co., Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Kyowa Kirin Announces Agreement with U.S. Administration to Reduce Treatment Costs for Americans
August 31, 2026
Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2026 Semi Annual
August 3, 2026
European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union
July 21, 2026
FDA Selects Kyowa Kirin for PreCheck Pilot Program to Accelerate Manufacturing Timelines and Enhance Supply Chain Resilience
June 30, 2026
New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome
June 29, 2026
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
June 10, 2026
FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH
May 14, 2026
Kyowa Kirin : Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2026 First Quarter
May 7, 2026
Kyowa Kirin : Consolidated Financial Summary (IFRS) Fiscal 2026 First Quarter
May 7, 2026
Kyowa Kirin : Results Presentation Fiscal 2026 First Quarter
May 7, 2026
CRYSVITA® Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program
May 6, 2026
Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA
April 30, 2026
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
April 24, 2026
Kyowa Kirin : (Correction / Correction of Numerical Data) Partial Correction of "Consolidated Financial Summary Fiscal 2025"
March 9, 2026
Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials
March 3, 2026
Grünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands
March 2, 2026
Cowellnex and Metagen Launch Joint Research Utilizing Independently Acquired High‑Precision Gut Microbiota Data
February 27, 2026
Kyowa Kirin : Announcement regarding the Partial amendments to the Articles of Incorporation (0B)
February 19, 2026
Kyowa Kirin : to Regain Control of Rocatinlimab Development and Commercialization Program
February 9, 2026
Kyowa Kirin : Announces Changes in Directors and Management Structure
February 9, 2026
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
January 30, 2026
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman
December 11, 2025
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
December 8, 2025
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
December 2, 2025
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
November 25, 2025
Kyowa Kirin : Announces Initiation of Phase 3 AOBA Study of KK8398 (Infigratinib) in Patients with Achondroplasia in Japan
November 21, 2025
Kyowa Kirin : Launches LUMICEF® Subcutaneous Injection 210 mg Pen in Japan
November 18, 2025
Kyowa Kirin : Launches Crysvita® Prefilled Syringe Formulation in Japan
November 18, 2025
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
November 13, 2025
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
November 3, 2025
Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting
November 3, 2025
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
October 30, 2025
Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan
October 28, 2025
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
October 24, 2025
Global Registry Data Show Meaningful Overall Survival Benefit in Patients with Advanced Cutaneous T-cell Lymphoma (CTCL) treated with POTELIGEO (mogamulizumab)
October 22, 2025
Menin Inhibitors Drug Market Report 2025: Price, Sales & Clinical Trials Insights 2024-2028 - Kura Oncology & Kyowa Kirin Progress with New Drug Applications
October 10, 2025
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
October 1, 2025
Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)
September 29, 2025
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
September 25, 2025
Kyowa Kirin Announces Late-Breaking Abstract Presentation at the European Academy of Dermatology and Venerology Congress
September 11, 2025
Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis
September 9, 2025
Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers
August 19, 2025
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
July 29, 2025
Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
July 7, 2025
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
June 12, 2025
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
June 1, 2025
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
May 22, 2025
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress
May 14, 2025